

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
ANDA 074286/S-004

Name: Desoximetasone Ointment USP
0.25%

Sponsor: Taro Pharmaceuticals, Inc.

Approval Date: May 16, 2000

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 074286/S-004

CONTENTS

Reviews / Information Included in this Review
--

Approval Letter	X
Tentative Approval Letter	
Labeling	
Labeling Review(s)	
Medical Review(s)	
Chemistry Review(s)	X
Bioequivalence Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Administrative & Correspondence Documents	X

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 074286/S-004

APPROVAL LETTER

ANDA 74-286/S-004

Taro Pharmaceuticals USA Inc.
Attention: Lorraine Sachs
5 Skyline Drive
Hawthorne, NY 10532

MAY 16 2000

Dear Ms. Sachs:

This refers to your supplemental new drug application dated November 25, 1999, submitted pursuant to 21 CFR 314.70, for Desoximetasone Ointment USP, 0.25%.


The supplemental application provides for the use of an alternate drug substance supplier (Taro Pharmaceutical Industries Ltd.).

We have completed the review of the supplemental application and it is approved.

We remind you that you must comply with the requirements for an approved abbreviated new drug application described in 21 CFR 314.80-81.

The material submitted is being retained in our files.

Sincerely yours,

 5/16/00
Rashmikant M. Patel, Ph.D.
Director
Division of Chemistry I
Office of Generic Drugs
Center for Drug Evaluation and Research

cc: ANDA #74286/S-004
Division File
Field Copy
HFD-92

Endorsements:

HFD-627/Liang-Lii Huang, Ph.D./5/8/00 *LL Huang 5/11/00*
HFD-627/P.Schwartz, Ph.D./5/8/00 *PS 5/12/00*
HFD-617/E. Hu, PM/ 5/11/00 *E 5/12/00*


V:\FIRMSNZ\TARO\LTRS&REV\74286S004LAP.DOC
F/T by: bc/5-11-00

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 074286/S-004

CHEMISTRY REVIEWS

1. CHEMISTRY REVIEW NO. # 1
2. ANDA # 74-286/S-004 (0.25%)
3. NAME AND ADDRESS OF APPLICANT:
Taro Pharmaceuticals USA, Inc.
Attention: Lorraine Sachs
5 Skyline Drive
Hawthorne, NY 10532
4. LEGAL BASIS OF SUBMISSION:
74-286: Desoximetasone Ointment USP, 0.25% was approved
June 7, 1996.
5. Supplements:
74-286/S-004 (0.25%)
6. PROPRIETARY NAME: None
7. NONPROPRIETARY NAME:
74-286: Desoximetasone Ointment USP, 0.25%
8. SUPPLEMENT(s) PROVIDE (s) FOR:
The use of an alternate drug substance supplier (Taro
Pharmaceutical Industries Ltd.).
9. AMENDMENTS AND OTHER DATES:
11-25-99 Supplements were submitted.
10. PHARMACOLOGICAL CATEGORY:
Synthetic topical corticosteroid
11. Rx or OTC: Rx
12. RELATED IND/NDA/DMF(s):
DMF 13861
13. DOSAGE FORM: Ointment
14. STRENGTH: 0.25%
15. CHEMICAL NAME AND STRUCTURE:
Desoximetasone. Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-
dihydroxy-16-methyl-, (11 β , 16 α)-.C₂₂H₂₉FO₄. 376.46. 382-67-2.
Anti-inflammatory.



16. RECORDS AND REPORTS: N/A

17. COMMENTS:

The supplemental application is approvable.

18. CONCLUSIONS AND RECOMMENDATIONS:

The supplemental application is approvable.

19. REVIEWER:

DATE COMPLETED:

Liang-Lii Huang, Ph.D.

May 8, 2000

Endorsed by P.Schwartz, Ph.D./ May 8, 2000

30. CONTROL NUMBERS: N/A
31. SAMPLES AND RESULTS: N/A
32. LABELING: N/A
33. ESTABLISHMENT INSPECTION:
EER: **acceptable** (OC recommendation, 12/3/99)
The proposed alternate supplier of the drug substance, Desoximetasone USP is:
Taro Pharmaceutical Industries Ltd.
14 Hakitor St.,
Haifa Bay 26110, Israel
34. BIOEQUIVALENCE STATUS: N/A
35. ENVIRONMENTAL IMPACT CONSIDERATIONS/CATEGORICAL EXCLUSION:
N/A
36. ORDER OF REVIEW:
The application submission(s) covered by this review was taken in the date order of receipt Yes XX
No
- If no, explain reason(s) below:

37. DMF CHECKLIST FOR ANDA #74-286 REVIEW # 1

<u>DMF #</u>	<u>DMF TYPE/SUBJECT/HOLDER</u>	<u>ACTION CODE</u>	<u>RESULT OF REVIEW REVIEW</u>	<u>DATE REVIEW COMPLETED</u>
13861	II/Desoximetasone/ Taro, Israel	1	adequate	4/26/00

Comments: reviewed by Liang-Lii Huang, Ph.D.

Comments:

Comments:

Comments:

Comments:

ACTION CODES: (1) DMF Reviewed. Other codes indicate why the
DMF was not reviewed, as follows:

- | | |
|---|---|
| (2) Type 1 DMF; | (3) Reviewed previously and no
revision since last review; |
| (4) Sufficient information
in application; | (5) Authority to reference not
granted; |
| (6) DMF not available; | (7) Other (explain under "Comments"). |

Liang-Lii Huang
Reviewer Signature

5/9/00
Date

cc: ANDA #74286/S-004
Division File
Field Copy

Endorsements:

HFD-627/Liang-Lii Huang, Ph.D./ 5/8/00 *LL Huang 5/9/00*
HFD-627/P.Schwartz, Ph.D./5/8/00 *PS 5/11/00*

V:\FIRMSNZ\TARO\LTRS&REV\74286S004RV1.DOC
May 9, 2000 *5/11/00*

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 074286/S-004

ADMINISTRATIVE and CORRESPONDENCE
DOCUMENTS



November 25, 1999

TARO PHARMACEUTICALS INC.
130 EAST DRIVE
BRAMALEA, ONTARIO
L6T 1C3

Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration
Document Control Room
Metro Park North II
7500 Standish Place, Room 150
Rockville MD 20857
USA

NDA NO. 74286 REF NO. SCC 004
NDA SUPPL FOR Supplier Addition

RE: **ANDA 74-286**
Desoximetasone Ointment USP, 0.25%
Supplement - Alternate Drug Substance Supplier

Dear Sir,

Reference is made to our approved Abbreviated New Drug Application (ANDA) for the above referenced product.

Pursuant to 21 CFR 314.70, Taro Pharmaceuticals Inc., (henceforth referred to as Taro), wishes to supplement the application to propose an alternate drug substance supplier to the currently approved supplier, (b) (4)

The name and address of the proposed alternate supplier of the drug substance, Desoximetasone USP, is:

Taro Pharmaceutical Industries Ltd.
14 Hakitor St.,
Haifa Bay 26110, Israel

The drug substance manufactured by Taro Pharmaceutical Industries Ltd., (henceforth referred to as Taro Israel), differs from that of the approved supplier, (b) (4) in the following ways:

i)
ii)

(b) (4)

(b) (4)

TELEPHONE
905-791-8276
1-800-268-1975
VOICE MAIL
905-791-5181
TELEFAX NO.
905-791-4767
905-791-5008

NOV 24 1999

1-30-99

In support of the proposed use of alternate source of desoximetasonone, Taro has manufactured a (b) (4) batch of Desoximetasonone Ointment USP, 0.25% using the drug substance manufactured by Taro Israel and has placed it on stability under accelerated and room temperature conditions. The master formula and manufacturing directions are as currently approved for this application. The data show that irrespective of the drug substance supplier a product is produced which meets all ANDA approved specifications.

The following documentation has been provided:

- i. Letter from Taro Pharmaceutical Industries Ltd. authorizing access to their Drug Master File for Desoximetasonone USP, DMF No. 13861 (pages 3-4).
- ii. Statement from Taro Israel regarding (b) (4) used in their (b) (4) process (pages 5-6).
- iii. Taro's proposed drug substance specification which includes a test and limit for (b) (4) (pages 7-8).
- iv. Taro's and Taro Israel's certificate of analysis for the Desoximetasonone USP raw material, (L) 8066-R, used in the manufacture of the exhibit batch of Desoximetasonone Ointment USP, 0.25% (L) 9F111 (pages 9-12).
- v. Executed manufacturing records for the manufacture of a (b) (4) batch of Desoximetasonone Ointment USP, 0.25%, (L) 9F111 and test results for in-process testing and bulk product testing (pages 13-21).
- vi. Executed packaging work orders for the packaging of 15 g and 60 g tubes (pages 22-31).

Desoxitmesone Ointment USP, 0.25%
ANDA 74-286
Alternate Drug Substance Supplier –
Taro Pharmaceutical Industries Ltd.

- vii. Finished packaged product certificates of analysis for Desoximetasone Ointment USP, 0.25%, for the approved tube sizes of 15 g and 60 g (pages 32-34).
- viii. Three (3) months accelerated (37°C, 75% RH), and three (3) months room temperature (25°C, 60% RH), stability data, for the 15 g and 60 g tubes, (L) 9F111 (pages 35-39).
- ix. Method SOP A-1023, "HPLC Quantitation of (b) (4) (b) (4) in Desoximetasone Drug Substance, USP" (pages 40-44).
- x. Correlation study comparing test data in the quantitation of (b) (4) to support the method transfer from Taro Israel to Taro (pages 45-46).

This concludes the supplement to this application. We trust the information provided is complete and sufficient for your review. Please note that Taro has submitted on June 29, 1999, a supplement to ANDA 73-193 for Desoximetasone Cream USP, 0.25% and ANDA 73-210 for Desoximetasone Cream USP, 0.05% to propose the same alternate drug substance supplier.

If you have any further concerns, please do not hesitate to contact the undersigned or our US agent:

Taro Pharmaceuticals U.S.A. Inc.
ATT. Lorraine Sachs, RAC
Associate Director, Regulatory Affairs
5 Skyline Drive,
Hawthorne, New York 10532
(914) 345-9001

Sincerely yours,
TARO PHARMACEUTICALS INC.



Derek Ganes, Ph.D.
Vice President, Regulatory Affairs

/ J. Hobbs
Cc. Acting Director, FDA, Office of International Programs

TARO PHARMACEUTICALS INC.
TELEPHONE
905-791-8276
1-800-268-1975
VOICE MAIL
905-791-5181
TELEFAX NO.
905-791-5008



November 25, 1999

TARO PHARMACEUTICALS INC.
130 EAST DRIVE
BRAMALEA, ONTARIO
L6T 1C3

Center for Drug Evaluation and Research
Food and Drug Administration
Central Document Room
12420 Parklawn Drive
Room 2-14
Rockville MD 20852
USA

Attention: FDA, Office of International Programs

RE: **ANDA 74-286**
Desoximetasone Ointment USP, 0.25%
Supplement - Alternate Drug Substance Supplier

Dear Sir,

The attached document is being submitted as the field copy for the above application.

Taro Pharmaceuticals Inc. hereby certifies that this field copy is a true copy of the technical information provided in this Supplement. If there are any questions in regard to this documentation, please do not hesitate to contact the undersigned or our US agent:

Taro Pharmaceuticals U.S.A. Inc.
ATT. Lorraine Sachs, RAC
Associate Director, Regulatory Affairs
5 Skyline Drive,
Hawthorne, New York
10532
(914) 345-9001

Sincerely yours,

TARO PHARMACEUTICALS INC.

Derek Ganes, Ph.D.
Vice President, Regulatory Affairs

TELEPHONE
905-791-8276
1-800-268-1975
VOICE MAIL
905-791-5181
TELEFAX NO.
905-791-4767
905-791-5008

ESTABLISHMENT EVALUATION REQUEST
SUMMARY REPORTApplication: **ANDA 74286/004**

Priority:

Org Code: **600**Stamp: **26-NOV-1999** Regulatory Due:

Action Goal:

District Goal: **26-APR-2000**Applicant: **TARO PHARMS (CA)**

Brand Name:

C/O **TARO PHARMACEUTICALS USA** Established Name: **DESOXIMETASONE****5 SKYLINE DR**

Generic Name:

HAWTHORNE, NY 10532Dosage Form: **ONT (OINTMENT)**Strength: **0.25%**FDA Contacts: **L. HUANG****(HFD-629)****301-827-5848 , Review Chemist**

Overall Recommendation:

Establishment: **9610271**DMF No: **13861****TARO PHARMACEUTICAL INDUST** AADA No:**14 HAKITOR STREET****HAIFA BAY 26110, , IS**Profile: **CSN**OAI Status: **NONE**Responsibilities: **DRUG SUBSTANCE
MANUFACTURER**Last Milestone: **SUBMITTED TO OC**Milestone Date: **03-DEC-1999**
